Leukemia Clinical Trials in New York

Showing 1781-1787 of 1,787 trials

Study for Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)

NCT00129948

This is a phase 2, single-arm, open-label, multi-center study to establish the safety and efficacy of Troxatyl™ (troxacitabine) administered as a continuous infusion for 5 days to subjects with AML.

Leukemia, Myeloid, Acute

SGX Pharmaceuticals, Inc.211 participantsStarted Jul 2005

La Jolla, California, United States • Los Angeles, California, United States • San Diego, California, United States +17 more locations

COMPLETEDPhase 1< 1 mile

CP-481,715 Nickel Allergy Study.

NCT00141180

To evaluate the suitability of contact allergy as a method for the evaluation of c-chemokine receptor-1 antagonist.

Dermatitis, Allergic Contact

Pfizer48 participantsStarted Sep 2003

Ann Arbor, Michigan, United States • New York, New York, United States • Austin, Texas, United States +2 more locations

Study for Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)

CP-481,715 Nickel Allergy Study.

Leukemia Trials in Other Cities

Study of DN-101 (Calcitriol) and Docetaxel in Subjects Previously Enrolled in Studies DN101-002 or DN101-004

Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.

Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase I Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile Of Lenalidomide (Revlimid®, CC-5013) With Pemetrexed In Subjects With Advanced Non-Small Cell Lung Cancer

Treatment of Hallucinosis/Psychosis in Parkinson's Disease by an Investigational Drug

Other Conditions in New York